Design
Review
Authors
Loading...
Supports vascular inflammation as a therapeutic target in CVD; leaves open whether angiotensin II or endothelin-1 inhibition alters outcomes in randomized trials.
Key points are not available for this paper at this time.
Virdis et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: